drugset / Trial / NCT07093866
Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II Study
Phase 2
Recruiting
20 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label，prospective，single-arm，phase 2 trial aims to evaluate the efficacy and safety of disitamab vedotin combined with abiraterone in patients with metastatic castration-resistant prostate cancer.
Timeline
- Start
- 2025-07-20
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |